Literature DB >> 31681963

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

Coleen K Cunningham1, Elizabeth J McFarland2, R Leavitt Morrison3, Edmund V Capparelli4, Jeffrey T Safrit5, Lynne M Mofenson5, Bonnie Mathieson6, Megan E Valentine7, Charlotte Perlowski7, Betsy Smith8, Rohan Hazra9, Lynette Purdue10, Petronella Muresan3,11, Paul A Harding2, Tapiwa Mbengeranwa12, Lisa-Gaye Robinson13, Andrew Wiznia14, Gerhard Theron15, Bob Lin16, Robert T Bailer16, John R Mascola16, Barney S Graham16.   

Abstract

BACKGROUND: Although mother-to-child human immunodeficiency virus (HIV) transmission has dramatically decreased with maternal antiretroviral therapy, breast milk transmission accounts for most of the 180 000 new infant HIV infections annually. Broadly neutralizing antibodies (bNAb) may further reduce transmission.
METHODS: A Phase 1 safety and pharmacokinetic study was conducted: a single subcutaneous (SC) dose of 20 or 40 mg/kg (Dose Groups 1 and 2, respectively) of the bNAb VRC01 was administered to HIV-exposed infants soon after birth. Breastfeeding infants (Dose Group 3) received 40 mg/kg SC VRC01 after birth and then 20 mg/kg/dose SC monthly. All infants received appropriate antiretroviral prophylaxis.
RESULTS: Forty infants were enrolled (21 in the United States, 19 in Africa). Subcutaneous VRC01 was safe and well tolerated with only mild-to-moderate local reactions, primarily erythema, which rapidly resolved. For multiple-dose infants, local reactions decreased with subsequent injections. VRC01 was rapidly absorbed after administration, with peak concentrations 1-6 days postdose. The 40 mg/kg dose resulted in 13 of 14 infants achieving the serum 50 micrograms (mcg)/mL target at day 28. Dose Group 3 infants maintained concentrations greater than 50 mcg/mL throughout breastfeeding.
CONCLUSIONS: Subcutaneous VRC01 as single or multiple doses is safe and well tolerated in very young infants and is suitable for further study to prevent HIV transmission in infants.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV-1; VRC01; broadly neutralizing antibodies; mother-to-child transmission of HIV; neonates

Mesh:

Substances:

Year:  2020        PMID: 31681963      PMCID: PMC7377284          DOI: 10.1093/infdis/jiz532

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  27 in total

1.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.

Authors:  Sung-Youl Ko; Amarendra Pegu; Rebecca S Rudicell; Zhi-yong Yang; M Gordon Joyce; Xuejun Chen; Keyun Wang; Saran Bao; Thomas D Kraemer; Timo Rath; Ming Zeng; Stephen D Schmidt; John-Paul Todd; Scott R Penzak; Kevin O Saunders; Martha C Nason; Ashley T Haase; Srinivas S Rao; Richard S Blumberg; John R Mascola; Gary J Nabel
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

3.  Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners.

Authors:  Kerry A Thomson; James Hughes; Jared M Baeten; Grace John-Stewart; Connie Celum; Craig R Cohen; Kenneth Ngure; James Kiarie; Nelly Mugo; Renee Heffron
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

4.  Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.

Authors:  Yunda Huang; Lily Zhang; Julie Ledgerwood; Nicole Grunenberg; Robert Bailer; Abby Isaacs; Kelly Seaton; Kenneth H Mayer; Edmund Capparelli; Larry Corey; Peter B Gilbert
Journal:  MAbs       Date:  2017-04-03       Impact factor: 5.857

5.  Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Authors:  Tongqing Zhou; Ivelin Georgiev; Xueling Wu; Zhi-Yong Yang; Kaifan Dai; Andrés Finzi; Young Do Kwon; Johannes F Scheid; Wei Shi; Ling Xu; Yongping Yang; Jiang Zhu; Michel C Nussenzweig; Joseph Sodroski; Lawrence Shapiro; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Authors:  Qing Zhu; Jason S McLellan; Nicole L Kallewaard; Nancy D Ulbrandt; Susan Palaszynski; Jing Zhang; Brian Moldt; Anis Khan; Catherine Svabek; Josephine M McAuliffe; Daniel Wrapp; Nita K Patel; Kimberly E Cook; Bettina W M Richter; Patricia C Ryan; Andy Q Yuan; JoAnn A Suzich
Journal:  Sci Transl Med       Date:  2017-05-03       Impact factor: 17.956

7.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.

Authors:  Rebecca M Lynch; Eli Boritz; Emily E Coates; Adam DeZure; Patrick Madden; Pamela Costner; Mary E Enama; Sarah Plummer; Lasonji Holman; Cynthia S Hendel; Ingelise Gordon; Joseph Casazza; Michelle Conan-Cibotti; Stephen A Migueles; Randall Tressler; Robert T Bailer; Adrian McDermott; Sandeep Narpala; Sijy O'Dell; Gideon Wolf; Jeffrey D Lifson; Brandie A Freemire; Robert J Gorelick; Janardan P Pandey; Sarumathi Mohan; Nicolas Chomont; Remi Fromentin; Tae-Wook Chun; Anthony S Fauci; Richard M Schwartz; Richard A Koup; Daniel C Douek; Zonghui Hu; Edmund Capparelli; Barney S Graham; John R Mascola; Julie E Ledgerwood
Journal:  Sci Transl Med       Date:  2015-12-23       Impact factor: 17.956

8.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.

Authors:  Hugo Mouquet; Louise Scharf; Zelda Euler; Yan Liu; Caroline Eden; Johannes F Scheid; Ariel Halper-Stromberg; Priyanthi N P Gnanapragasam; Daniel I R Spencer; Michael S Seaman; Hanneke Schuitemaker; Ten Feizi; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-30       Impact factor: 11.205

9.  Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Authors:  Kenneth H Mayer; Kelly E Seaton; Yunda Huang; Nicole Grunenberg; Abby Isaacs; Mary Allen; Julie E Ledgerwood; Ian Frank; Magdalena E Sobieszczyk; Lindsey R Baden; Benigno Rodriguez; Hong Van Tieu; Georgia D Tomaras; Aaron Deal; Derrick Goodman; Robert T Bailer; Guido Ferrari; Ryan Jensen; John Hural; Barney S Graham; John R Mascola; Lawrence Corey; David C Montefiori
Journal:  PLoS Med       Date:  2017-11-14       Impact factor: 11.069

10.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Authors:  Jinghe Huang; Gilad Ofek; Leo Laub; Mark K Louder; Nicole A Doria-Rose; Nancy S Longo; Hiromi Imamichi; Robert T Bailer; Bimal Chakrabarti; Shailendra K Sharma; S Munir Alam; Tao Wang; Yongping Yang; Baoshan Zhang; Stephen A Migueles; Richard Wyatt; Barton F Haynes; Peter D Kwong; John R Mascola; Mark Connors
Journal:  Nature       Date:  2012-09-18       Impact factor: 49.962

View more
  11 in total

1.  Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity.

Authors:  Iara M Backes; Brook K Byrd; Matthew D Slein; Chaya D Patel; Sean A Taylor; Callaghan R Garland; Scott W MacDonald; Alejandro B Balazs; Scott C Davis; Margaret E Ackerman; David A Leib
Journal:  J Exp Med       Date:  2022-09-26       Impact factor: 17.579

2.  Pediatric AIDS-Therapeutic Successes Built on a Foundation of Pediatric Clinical Pharmacology with Pharmacokinetic-Pharmacodynamic Modeling.

Authors:  Edmund V Capparelli
Journal:  J Pediatr Pharmacol Ther       Date:  2022-08-19

3.  Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.

Authors:  Joseph P Casazza; Evan M Cale; Sandeep Narpala; Galina V Yamshchikov; Emily E Coates; Cynthia S Hendel; Laura Novik; LaSonji A Holman; Alicia T Widge; Preeti Apte; Ingelise Gordon; Martin R Gaudinski; Michelle Conan-Cibotti; Bob C Lin; Martha C Nason; Olga Trofymenko; Shinyi Telscher; Sarah H Plummer; Diane Wycuff; William C Adams; Janardan P Pandey; Adrian McDermott; Mario Roederer; Avery N Sukienik; Sijy O'Dell; Jason G Gall; Britta Flach; Travis L Terry; Misook Choe; Wei Shi; Xuejun Chen; Florence Kaltovich; Kevin O Saunders; Judy A Stein; Nicole A Doria-Rose; Richard M Schwartz; Alejandro B Balazs; David Baltimore; Gary J Nabel; Richard A Koup; Barney S Graham; Julie E Ledgerwood; John R Mascola
Journal:  Nat Med       Date:  2022-04-11       Impact factor: 87.241

4.  Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.

Authors:  Elizabeth J McFarland; Coleen K Cunningham; Petronella Muresan; Edmund V Capparelli; Charlotte Perlowski; Patricia Morgan; Betsy Smith; Rohan Hazra; Lynette Purdue; Paul A Harding; Gerhard Theron; Hilda Mujuru; Allison Agwu; Murli Purswani; Mobeen H Rathore; Britta Flach; Alison Taylor; Bob C Lin; Adrian B McDermott; John R Mascola; Barney S Graham
Journal:  J Infect Dis       Date:  2021-12-01       Impact factor: 7.759

5.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Authors:  Lawrence Corey; Peter B Gilbert; Michal Juraska; David C Montefiori; Lynn Morris; Shelly T Karuna; Srilatha Edupuganti; Nyaradzo M Mgodi; Allan C deCamp; Erika Rudnicki; Yunda Huang; Pedro Gonzales; Robinson Cabello; Catherine Orrell; Javier R Lama; Fatima Laher; Erica M Lazarus; Jorge Sanchez; Ian Frank; Juan Hinojosa; Magdalena E Sobieszczyk; Kyle E Marshall; Pamela G Mukwekwerere; Joseph Makhema; Lindsey R Baden; James I Mullins; Carolyn Williamson; John Hural; M Juliana McElrath; Carter Bentley; Simbarashe Takuva; Margarita M Gomez Lorenzo; David N Burns; Nicole Espy; April K Randhawa; Nidhi Kochar; Estelle Piwowar-Manning; Deborah J Donnell; Nirupama Sista; Philip Andrew; James G Kublin; Glenda Gray; Julie E Ledgerwood; John R Mascola; Myron S Cohen
Journal:  N Engl J Med       Date:  2021-03-18       Impact factor: 176.079

6.  Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials.

Authors:  Eliza D Hompe; Jesse F Mangold; Amit Kumar; Joshua A Eudailey; Erin McGuire; Barton F Haynes; M Anthony Moody; Peter F Wright; Genevieve G Fouda; Elena E Giorgi; Feng Gao; Sallie R Permar
Journal:  mSphere       Date:  2020-06-03       Impact factor: 4.389

Review 7.  Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities.

Authors:  Yubin Liu; Wei Cao; Ming Sun; Taisheng Li
Journal:  Emerg Microbes Infect       Date:  2020-01-27       Impact factor: 7.163

8.  Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.

Authors:  Amit Kumar; Elena E Giorgi; Joshua J Tu; David R Martinez; Joshua Eudailey; Michael Mengual; Manukumar Honnayakanahalli Marichannegowda; Russell Van Dyke; Feng Gao; Sallie R Permar
Journal:  PLoS Pathog       Date:  2021-04-02       Impact factor: 7.464

Review 9.  Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.

Authors:  Gabriel Siracusano; Lucia Lopalco
Journal:  Cells       Date:  2021-12-28       Impact factor: 6.600

10.  Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.

Authors:  Jerry Li; Mina Nikanjam; Coleen K Cunningham; Elizabeth J McFarland; Emily E Coates; Katherine V Houser; Bob C Lin; Adrian B McDermott; Britta Flach; Lucio Gama; Richard A Koup; Barney S Graham; John R Mascola; Julie E Ledgerwood; Edmund V Capparelli
Journal:  Clin Pharmacol Ther       Date:  2020-10-03       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.